Shares of Johnson & Johnson (NYSE:JNJ) ended Monday session in red amid volatile trading. The shares closed down -1.03 points or -0.87% at $117.78 with 6.00 million shares getting traded. Post opening the session at $118.63, the shares hit an intraday low of $117.56 and an intraday high of $118.64 and the price vacillated in this range throughout the day. The company has a market cap of $320.48 billion and the numbers of outstanding shares have been calculated to be 2.74 billion shares.
Johnson & Johnson (JNJ) on Sept. 20, 2016 announced a new five-year commitment to help advance the United Nations Sustainable Development Goals to help improve the health and well-being of men, women and children around the world. Johnson & Johnson is dedicating its expertise and innovations to ignite global partnerships and catalyze efforts through a variety of new implementation plans, targets and metrics. The announcement comes along with an expanded commitment by Johnson & Johnson to further strengthen the resilience of refugee and displaced children and their families in Syria and its neighboring countries where the need is greatest.
“Johnson & Johnson is committed to creating greater access to quality health care across the globe,” said Johnson & Johnson Chairman and CEO Alex Gorsky. “Beyond developing medicines, equipment and vaccines, we’re in communities helping expectant mothers take better care of themselves and their babies during pregnancy. We’re training nurses and doctors to identify and treat diseases, and also funding medical research. We’re proud to take a leading role with the world community in this effort, which will go a long way toward creating a healthier society.”
Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) ended Monday session in green amid volatile trading. The shares closed up +1.83 points or 3.16% at $59.66 with 5.96 million shares getting traded. Post opening the session at $59.01, the shares hit an intraday low of $58.00 and an intraday high of $61.43 and the price vacillated in this range throughout the day. The company has a market cap of $2.71 billion and the numbers of outstanding shares have been calculated to be 52.89 million shares.
Sarepta Therapeutics Inc (SRPT) on September 21, 2016 announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) has issued two favorable decisions for Sarepta in the composition of matter patent interferences for exon 51 (Interference No. 106,008) and exon 53 (Interference No. 106,007). These decisions, subject to appeal, finally refused all of BioMarin’s claims in the exon 51 and exon 53 composition of matter interferences that, if granted, could have formed a basis for a claim of infringement against eteplirsen and SRP-4053. The PTAB decision for exon 53 allows BioMarin to obtain a narrow composition of matter claim, however, SRP-4053 does not infringe this claim. The PTAB ended the exon 51 interference in our favor based on a statute of limitations bar.
Accordingly, the PTAB did not decide the patentability of the Sarepta exon 51 patents involved in the interference (U.S. Patent Nos. 7,807,816 and 7,960,541). Although the PTAB did decide to cancel the Sarepta exon 53 patent involved in the interference (U.S. Patent No. 8,455,636), that exon 53 decision does not negatively impact Sarepta’s key composition of matter patent protection for EXONDYS 51 and SRP-4053 (U.S. Patent Nos. 9,018,368 and 9,024,007, respectively). Neither of these key patents are involved in any pending interferences and are presumed valid and enforceable. These patents expire in June 2025, not including any potential patent term extension or regulatory exclusivity that would extend this date.